))
DME/Retina Edition: Top Headlines for Week of July 8, 2024
Manage episode 428373684 series 3560281
Healio에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Healio 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:
FDA approves Vabysmo prefilled syringe for retinal diseases
VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates
FDA approves Eylea biosimilar FYB203/Ahzantive
VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study
ANI Pharmaceuticals to acquire Alimera Sciences
References:
Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Healio Interviews
Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.
115 에피소드
공유
